An interview with Pressure BioSciences' founder and chief executive Richard Schumacher can be viewed here: http://www.biomedreports.com/2012022790166/video-ceo-of-pressure-biosciences-sees-firms-momentum-continuing-to-build-in-2012.html
The life sciences company develops and commercializes pressure cycling technology (PCT) for use in the mass spectrometry market, where end uses range from forensics, biomarker discovery, to histology and counter-bioterror applications.
The technology uses rapid cycles of hydrostatic pressure to control biomolecular interactions, allowing for a high degree of precision, speed and reproducibility, the company said.
Earlier this month, Pressure BioSciences closed on an $800,000 private placement financing.
The placement consisted of the sale of 971,867 shares of restricted common stock, and 485,937 warrants to purchase further common stock.
Last month, the life sciences company saw its shares surge after it announced the signing of a co-marketing and selling agreement with Digilab, expected to boost its sales efforts significantly.
The companies said they intend to co-market and sell their respective product lines worldwide, including in industry publications, at scientific meetings, on each company's website, through common collaborator studies, at key industry trade shows, and in visits to customer sites.